Canada Markets open in 1 hr 13 mins

Syndax Pharmaceuticals, Inc. (SNDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.14-0.51 (-3.26%)
At close: 4:00PM EDT

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
http://www.syndax.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees35

Key Executives

NameTitlePayExercisedYear Born
Dr. Briggs W. Morrison M.D.CEO & Director848.43kN/A1960
Mr. Michael A. MetzgerPres, COO & Director795.35kN/A1971
Dr. Michael L. MeyersChief Medical Officer & Sr. VP599.3kN/A1951
Dr. Peter OrdentlichCo-Founder & Chief Scientific OfficerN/AN/A1969
Dr. Richard A. HeymanCo-FounderN/AN/A1957
Dr. Ronald M. Evans Ph.D.Co-Founder, Advisor and Chair of Scientific Advisory BoardN/AN/AN/A
Dr. Michael Downes Ph.D.Co-FounderN/AN/AN/A
Ms. Daphne KarydasChief Financial OfficerN/AN/A1972
Mr. Luke J. AlbrechtSr. VP, Gen. Counsel & Sec.N/AN/A1979
Dr. Edward A. Sausville M.D., Ph.D.AdvisorN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Syndax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.